|
|
Article: Ads may jolt pill sales: The FDA approved Takeda Pharmaceuticals' Rozerem almost a year ago, but the firm held off heavy marketing of the insomnia pill until after talking about it with doctors. It has side effects, but it is.
- Article from:
- Chicago Tribune (Chicago, IL)
- Article date:
- July 16, 2006
CopyrightCOPYRIGHT 2006 Chicago Tribune. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Bruce Japsen
Jul. 16--Hoping to help Americans snooze while also putting to rest controversies dogging the crowded group of prescription sleeping pills, a Chicago-area drugmaker this week will launch a nearly $100 million consumer ad campaign for its insomnia pill. Takeda Pharmaceuticals North America Inc. on Monday will launch an ad campaign directed at consumers for its new sleeping pill, Rozerem, which the Food and Drug Administration approved last year as the first sleeping medication not designated as a controlled substance, therefore lacking potential for abuse. The company and studies indicate the drug lacks the risk of chemical abuse or ...
Related newspaper, magazine, and journal articles:
|
|
Article: Study Demonstrated ROZEREM(TM) (ramelteon) Does Not Affect ...
PR Newswire;
June 13, 2007 ;
700+ words
... ... studies presented today demonstrated that ROZEREM did not affect body sway at peak plasma ... data are important because they show that ROZEREM may be a safe sleep medication for the ... patients' memories were not affected by ROZEREM the next morning," said Gary Zammit ...
|
|